{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:47:34Z","timestamp":1789001254939,"version":"build-2803163510"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2019,4,2]]},"abstract":"\n Background<\/jats:title>\n Vascular risk factors have been associated with differences in cognitive performance in epidemiological studies, but evidence in patients with coronary heart disease is more limited.<\/jats:p>\n <\/jats:sec>\n \n Methods and Results<\/jats:title>\n \n The Montreal Cognitive Assessment score obtained 3.2\u00b10.37\u00a0years after randomization to darapladib, a reversible inhibitor of lipoprotein phospholipase A\n 2<\/jats:sub>\n or placebo was evaluated for 10\u00a0634 patients with coronary heart disease from 38 countries in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. The Montreal Cognitive Assessment scores for darapladib and placebo groups were similar (mean\u00b1\n SD<\/jats:styled-content>\n , 25.3\u00b13.84 versus 25.4\u00b13.73, respectively;\n P<\/jats:italic>\n =0.27) and the adjusted odds ratio (\n OR<\/jats:styled-content>\n ) for mild cognitive impairment (Montreal Cognitive Assessment score <26) was 1.00 (95%\n CI<\/jats:styled-content>\n , 0.93\u20131.09). Mild cognitive impairment was more likely with increasing age (\n OR<\/jats:styled-content>\n , 1.33 [1.27\u20131.41], +5\u00a0years after 65). For other baseline clinical characteristics, the strongest independent predictors of cognitive impairment were education (\u22648\u00a0years versus college\/university,\n OR<\/jats:styled-content>\n , 2.95 [2.60\u20133.35]; >8\u00a0years\/trade school versus college\/university,\n OR<\/jats:styled-content>\n , 1.38 [1.25\u20131.52] and geographic grouping). Cardiovascular risk factors independently associated with cognitive impairment were history of stroke (\n OR<\/jats:styled-content>\n , 1.43 [1.20\u20131.71]); <2.5\u00a0hours of moderate or vigorous intensity exercise\/week (\n OR<\/jats:styled-content>\n , 1.19 [1.04\u20131.37]); high\u2010density lipoprotein cholesterol <1.16\u00a0mmol\/L (\n OR<\/jats:styled-content>\n , 1.19 [1.04\u20131.37]); diabetes mellitus requiring treatment (\n OR<\/jats:styled-content>\n , yes versus no: 1.15 [1.05\u20131.26]); and history of hypertension (\n OR<\/jats:styled-content>\n , 1.12 [1.02\u20131.23]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In patients with stable coronary heart disease, cognitive performance was associated with modifiable cardiovascular risk factors, educational level, and global region, but was not influenced by darapladib.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial Registration<\/jats:title>\n \n URL<\/jats:styled-content>\n :\n http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n . Unique identifier:\n NCT<\/jats:styled-content>\n 00799903.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1161\/jaha.118.010641","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T09:00:30Z","timestamp":1553245230000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease"],"prefix":"10.1161","volume":"8","author":[{"given":"Ralph A. H.","family":"Stewart","sequence":"first","affiliation":[{"name":"Green Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand"},{"name":"University of Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes","family":"Held","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden"},{"name":"Uppsala Clinical Research Center (UCR) Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Krug\u2010Gourley","sequence":"additional","affiliation":[{"name":"Metabolic Pathways and Cardiovascular Medicine Delivery Unit GlaxoSmithKline Research and Development Collegeville PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Waterworth","sequence":"additional","affiliation":[{"name":"Department of Genetics GlaxoSmithKline Medicines Research Centre Upper Merion Philadelphia PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Stebbins","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chiswell","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute Durham NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Hagstrom","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden"},{"name":"Uppsala Clinical Research Center (UCR) Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre University of Alberta Edmonton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences Cardiology Uppsala University Uppsala Sweden"},{"name":"Uppsala Clinical Research Center (UCR) Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"White","sequence":"additional","affiliation":[{"name":"Green Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand"},{"name":"University of Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909087"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67889-0"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68542-5"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318227b227"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-153-3-201008030-00258"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000148"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004798"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318295d776"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2015.08.001"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20721"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.04.032"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12515-z"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep33073"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315878"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003407"},{"key":"e_1_3_2_17_2","unstructured":"ClinicalStudyDataRequest.com (CSDR) . ClinicalStudy DataRequest.com. 2019. Available at: https:\/\/www.clinicalstudydatarequest.com\/Default.aspx. Accessed December 1 2018."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht258"},{"key":"e_1_3_2_19_2","volume-title":"Physical Activity Guidelines Advisory Committee Report, 2008","author":"Physical Activity Guidelines Advisory Committee","year":"2008","unstructured":"Physical Activity Guidelines Advisory Committee . Physical Activity Guidelines Advisory Committee Report, 2008. Washington, D.C.: US Department of Health and Human Services; 2008."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw125"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"e_1_3_2_22_2","first-page":"CD010775","article-title":"Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias","volume":"29","author":"Davis DHJ","year":"2015","unstructured":"Davis DHJ, Creavin ST, Yip JLY, Noel\u2010Storr AH, Brayne C, Cullum S. Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias. Cochrane Database Syst Rev. 2015;29:CD010775.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31363-6"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318230208a"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.3.416"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038268"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.014"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gls187"},{"key":"e_1_3_2_29_2","volume-title":"FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol\u2010Lowering Statin Drugs","author":"U.S. Department of Health and Human Services","year":"2012","unstructured":"U.S. Department of Health and Human Services . FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol\u2010Lowering Statin Drugs. Silver Spring, MD: US Food and Drug Administration; 2012."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2016.3162"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.118.010641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:43:43Z","timestamp":1715600623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.118.010641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,4,2]]}},"alternative-id":["10.1161\/JAHA.118.010641"],"URL":"https:\/\/doi.org\/10.1161\/jaha.118.010641","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"2018-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e010641"}}